Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle-Control Topical Solution Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers

NCT03502434
View directory record Official record
Conditions
Tendinopathy
Interventions
SM04755, Vehicle, White Petrolatum, Sodium lauryl sulfate
Drug · Other
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

NCT04638660
View directory record Official record
Conditions
Dim Light Vision Disturbances
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo)
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Newport Beach, California • Petaluma, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 1Phase 2 Interventional

Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.

NCT00721695
View directory record Official record
Conditions
Cataract Extraction
Interventions
OMS302, OMS302-PE, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Redding, California • Bloomington, Minnesota • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

NCT00784719
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
CP-690,550, Cyclosporine, CP-690,550 Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Sep 6, 2026, 6:36 AM EDT
Terminated Phase 2 Interventional Results available

A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

NCT04806503
View directory record Official record
Conditions
Presbyopia
Interventions
UNR844, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 55 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Laguna Hills, California • Newport Beach, California • Largo, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

NCT03691649
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Phoenix, Arizona • Sun City, Arizona • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

NCT05848128
View directory record Official record
Conditions
Dry Eye Syndromes, Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions
5% Tavilermide ophthalmic solution, Vehicle ophthalmic solution
Drug · Other
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
29
States / cities
Phoenix, Arizona • Glendale, California • Murrieta, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2024 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

NCT04030962
View directory record Official record
Conditions
Dry Eye Disease, Dry Eye Syndrome
Interventions
AGN-242428, AGN-231868, AGN-242428 Vehicle, AGN-231868 Vehicle, Lifitegrast 5% Ophthalmic Solution
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 6, 2026, 6:36 AM EDT
Recruiting Phase 2 Interventional

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

NCT07503886
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
DFL24498, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Chandler, Arizona • Azusa, California • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03687372
View directory record Official record
Conditions
Common Wart
Interventions
A-101, vehicle
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 2 Interventional

Study to Assess the Safety and Efficacy of Benzocaine for Pain Relief in Children Presenting With Acute Otitis Media

NCT02092454
View directory record Official record
Conditions
Pain, Acute Otitis Media
Interventions
Benzocaine, Placebo
Drug
Lead sponsor
Otic Therapy, LLC
Industry
Eligibility
2 Months to 12 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Clearwater, Florida • Gresham, Oregon • Murray, Utah
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion

NCT02061813
View directory record Official record
Conditions
Head Lice
Interventions
Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate, Saline 0.9%, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 6, 2026, 6:36 AM EDT
Recruiting Phase 3 Interventional

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

NCT07246590
View directory record Official record
Conditions
Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions
VP-102, Vehicle
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Saint Augustine, Florida • Plainfield, Indiana • Hunt Valley, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects

NCT01984775
View directory record Official record
Conditions
Psoriasis
Interventions
GSK2894512 cream, Vehicle cream, Positive control, Negative control
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes

NCT03846453
View directory record Official record
Conditions
Dry Eye
Interventions
HL036 Ophthalmic Solution, Placebo
Biological
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Phoenix, Arizona • Newport Beach, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

ALC-919 For The Treatment Of Common Warts

NCT02483455
View directory record Official record
Conditions
Verruca Vulgaris
Interventions
2014-ALC-919-US, Vehicle-Control Topical Solution
Drug
Lead sponsor
Veloce BioPharma LLC
Industry
Eligibility
8 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fort Washington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.

NCT03809611
View directory record Official record
Conditions
Presbyopia
Interventions
UNR844-Cl, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Mission Hills, California • Newport Beach, California • Largo, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

NCT04024891
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
4
States / cities
Pittsburg, Kansas • Lexington, Kentucky • Athens, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

NCT04268069
View directory record Official record
Conditions
Dry Eye Disease
Interventions
PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Shelby, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis

NCT02965781
View directory record Official record
Conditions
Herpes Labialis, Cold Sore
Interventions
SADBE, Placebo
Drug · Other
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye

NCT05109702
View directory record Official record
Conditions
Dry Eye
Interventions
0.25% Tanfanercept Ophthalmic Solution, Placebo
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 4 Interventional Results available

CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial

NCT00847912
View directory record Official record
Conditions
Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms, Skin Diseases, Neoplasms, Basal Cell, Neoplasms, Squamous Cell, Carcinoma
Interventions
5-fluorouracil, Placebo, vehicle control
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis

NCT01431820
View directory record Official record
Conditions
Distal and Lateral Subungual Onychomycosis
Interventions
Luliconazole Solution, 10%, Vehicle Solution
Drug
Lead sponsor
Topica Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2015 · Synced Sep 6, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)

NCT03889886
View directory record Official record
Conditions
Dry Eye
Interventions
SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%), Vehicle
Drug
Lead sponsor
Silk Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
26
States / cities
Azusa, California • Garden Grove, California • Mission Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 6, 2026, 6:36 AM EDT